Physician profile
Michael S Hull
NPI 1396891743
$641,562.91
in general payments reported to CMS, 2019-2025
30 companies · $878 in 2025
The $878 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $957 · 2020: $163 · 2021: $438 · 2022: $698 · 2023: $270 · 2024: $638K · 2025: $878.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $637K · Food and Beverage: $2,010 · Education: $21.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $637,274.79 |
| Food and Beverage | $2,009.85 |
| Education | $21.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cipla USA INC. | $637,274.79 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $556.37 | 2019-2025 | Ofev, Jascayd |
| Actelion Pharmaceuticals US, INC. | $508.35 | 2019-2022 | |
| Glaxosmithkline, LLC. | $441.85 | 2019-2025 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $381.35 | 2019-2025 | Breztri, Tezspire |
| Baxter Healthcare | $268.94 | 2022-2025 | Hillrom - Monarch Airway Clearance System, Hillrom - Life 2000 Ventilation System |
| Genzyme Corporation | $228.72 | 2021-2025 | |
| Grifols USA, LLC | $202.97 | 2019-2023 | Prolastin-C Liquid |
| Regeneron Healthcare Solutions, INC. | $184.86 | 2022-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $158.21 | 2019-2025 | |
| Csl Behring | $150.02 | 2019-2023 | Haegarda |
| Sunovion Pharmaceuticals INC. | $121.84 | 2019 | |
| Insmed, INC. | $113.83 | 2021-2025 | Arikayce, Brinsupri |
| Fisher & Paykel Healthcare INC | $105.98 | 2019-2023 | Fisher & Paykel Healthcare |
| Sun Pharmaceutical Industries INC. | $97.95 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inogen, INC. | $89.04 | 2022-2025 | |
| Amgen INC. | $87.89 | 2022-2025 | Tezspire |
| Mylan Specialty L.P. | $84.14 | 2019-2023 | Yupelri |
| Pfizer INC. | $72.60 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $71.86 | 2024-2025 | Capvaxive, Winrevair |
| Harmony Biosciences LLC | $61.49 | 2023 | Wakix |
| Vifor Pharma, INC. | $55.79 | 2024 | Zemaira |
| Takeda Pharmaceuticals U.S.A., INC. | $53.30 | 2021-2024 | Glassia |
| United Therapeutics Corporation | $47.41 | 2024-2025 | Tyvaso, Tyvaso |
| Janssen Pharmaceuticals, INC | $39.34 | 2019 | |
| Viatris Specialty LLC | $35.06 | 2025 | Yupelri |
| Advanced Respiratory, INC | $24.13 | 2020 | |
| Philips North America LLC | $17.68 | 2023 | |
| Chiesi USA, INC. | $15.14 | 2021 | |
| Circassia INC. | $12.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Hull listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.